Mediastinal Neoplasms Clinical Trial
Official title:
Phase 2 Study of Weekly Topotecan With Docetaxel for Recurrent Small Cell Lung Cancer
The purposes of this study are:
- To determine the overall response rate of patients treated with at least 2 cycles of
this regimen.
- To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
The main objective of this study was to determine the overall response rate of patients
treated with at least 2 cycles of topotecan and docetaxel. The secondary objectives were to
determine the feasibility and toxicities of this combination. The final secondary objective
is overall survival for patients that received 2 or more cycles.
Methods: Eligible pts with recurrent small cell lung cancer had to be at least 3 months from
initial treatment. Pts received Docetaxel 30 mg/m2 IV followed by Topotecan 3 mg/m2 IV Days 1
and 8 of a 21 day cycle. Disease assessment was done every 2 cycles. Toxicity was measured
each cycle.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00199082 -
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
|
Phase 4 | |
| Terminated |
NCT02499952 -
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
|
Phase 2 | |
| Recruiting |
NCT03521986 -
Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS
|
Phase 3 |